AAAAAA
Results:
1-7
|
Results: 7
Authors:
Deacon, CF
Danielson, P
Klarskov, L
Olesen, M
Holst, JJ
Citation: Cf. Deacon et al., Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs, DIABETES, 50(7), 2001, pp. 1588-1597
Authors:
Vilsboll, T
Krarup, T
Deacon, CF
Madsbad, S
Holst, JJ
Citation: T. Vilsboll et al., Reduced postprandial concentrations of intact biologically active gluccagon-like peptide 1 in type 2 diabetic patients, DIABETES, 50(3), 2001, pp. 609-613
Authors:
Meier, JJ
Huking, K
Holst, JJ
Deacon, CF
Schmiegel, WH
Nauck, MA
Citation: Jj. Meier et al., Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes, DIABETES, 50(11), 2001, pp. 2497-2504
Authors:
Hartmann, B
Harr, MB
Jeppesen, PB
Wojdemann, M
Deacon, CF
Mortensen, PB
Holst, JJ
Citation: B. Hartmann et al., In vivo and in vitro degradation of glucagon-like peptide-2 in humans, J CLIN END, 85(8), 2000, pp. 2884-2888
Authors:
Deacon, CF
Nauck, MA
Meier, J
Hucking, K
Holst, JJ
Citation: Cf. Deacon et al., Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide, J CLIN END, 85(10), 2000, pp. 3575-3581
Authors:
Deacon, CF
Holst, JJ
Carr, RD
Citation: Cf. Deacon et al., Glucagon-like peptide-1: A basis for new approaches to the management of diabetes, DRUGS TODAY, 35(3), 1999, pp. 159-170
Authors:
Hansen, L
Deacon, CF
Orskov, C
Holst, JJ
Citation: L. Hansen et al., Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying theL cells of the porcine intestine, ENDOCRINOL, 140(11), 1999, pp. 5356-5363
Risultati:
1-7
|